Introducing CODE3
Drawing on 12 years of rigorous research and clinical refinement, our patent-pending formula (63/800,093) uses Tranexamic Acid, Bakuchiol, and Quercetin to correct abnormal pigment while preserving normal melanin — the pigment your skin needs for UV protection and even tone. Unlike hydroquinone, CODE3 works upstream of tyrosinase, targeting only the pathological signals that cause excess pigment.
CODE3 Partnership Program
CODE3 is available through our Partnership Program at select plastic surgery practices. See our list of providers offering premium skin care.
Participating Providers
-
Dr. Melinda Costa
2516 Samaritan Dr Suite N, San Jose, CA 95124
Partnership Benefits
Cutting-edge formula
Co-marketed product
Win-win practice economics
Key Ingredients
Tranexamic Acid
Blocks the abnormal plasmin signal that triggers excess melanocyte activation — without touching tyrosinase. Normal melanin production is not directly suppressed.
Bakuchiol
Calms inflammatory cytokines that pathologically overactivate melanocytes. Preserves normal skin barrier and pigment — without the irritation of retinoids.
Quercetin
Neutralizes excess reactive oxygen species that abnormally trigger melanogenesis. Protects healthy melanocytes from oxidative damage.
The Science: TXA for Post-Procedure-Recovery
TXA: Rosacea Inflammation Reduction
A randomized, vehicle controlled, split-face study was performed on 30 rosacea patients. This study involved 2 weeks of 3% tranexamic acid solution treatment and vehicle control treatment. Individuals with rosacea expressed a higher baseline level of PAR-2 compared with normal skin. Tranexamic acid improved the permeability barrier function in rosacea patients.
Learn MoreTXA: Post Microneedling Study
A split-face randomized trial (n=40) found that microneedling plus 10% topical tranexamic acid produced substantially greater melasma improvement by 8 weeks than microneedling plus control (about 66% vs 21% improvement in mMASI).
Learn MoreTranexamic Acid: Reduce Post-Surgical Procedure Bruising
A 54-patient randomized, double-blind, placebo-controlled trial evaluated topical 3% TXA applied intraoperatively during facial/scalp reconstruction after skin-cancer excision. The TXA group had lower measured blood loss (11.4 mL vs 17.6 mL) and far less post-procedure bruising/ecchymosis (3.8% vs 82.1%).
Learn MoreThe Science: Skin Evening & Anti-Aging
Topical Tranexamic Acid as a Promising Treatment for Melasma
Demonstrated that 3% topical TA safely and effectively reduces hyperpigmentation in melasma patients, with significant MASI score improvements over 12 weeks.
Read Full Paper5% Tranexamic Acid vs. 3% Hydroquinone in Melasma: A Randomized Trial
This RCT compared 5% TA solution with 3% hydroquinone cream in Indian skin, showing equivalent MASI reduction but higher patient satisfaction and fewer adverse effects with TA.
Read Full PaperTXA in Melasma Management: Systematic Review & Meta-Analysis
A comprehensive meta-analysis of RCTs confirming that topical and oral TXA significantly improve melasma outcomes with a favorable safety profile.
Read Full PaperTXA for Anti-Aging Benefits
An injectable gel made of hyaluronic acid, niacinamide, and tranexamic acid that, in a study of 49 women, noticeably improved skin hydration, firmness, smoothness, and evenness over 70 days.
Read Full PaperTestimonials
*Everybody responds a little bit differently to topical products. If you're one of those individuals who notices irritation, we recommend to reduce or stop use.